Companies / Japan
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
Renewed Speculation Over Japan's Sawai
June 2006 | Company Finance AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
Local media sources have again claimed that the world's largest generic drugmaker, Israel-based Teva, is concisidering a bid for leading Japanese generics firm Sawai. Other international producers including Sandoz are also eyeing the market, which is set to rapidly improve its current 6% share of Japan's US$60bn annual drug sales.